Clinical Trial Update: A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects [Phase 2]

View source ↗

Summary

A randomized, dose-ranging Phase 2 trial of Alferon LDO in asymptomatic HIV-infected subjects was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Alferon LDO (Interferon alfa)

Snippet

Sponsor: AIM ImmunoTech Inc. | Conditions: HIV Infections | Phase 2 | Status: TERMINATED